MindWalk (NASDAQ:HYFT) Stock Rating Upgraded by Wall Street Zen

MindWalk (NASDAQ:HYFTGet Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other analysts have also issued reports on HYFT. HC Wainwright restated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Zacks Research downgraded MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.

View Our Latest Report on MindWalk

MindWalk Price Performance

NASDAQ:HYFT opened at $1.41 on Friday. The firm has a market cap of $65.86 million, a price-to-earnings ratio of -6.41 and a beta of 0.84. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average is $1.46 and its two-hundred day moving average is $1.39. MindWalk has a 12-month low of $0.99 and a 12-month high of $3.25.

MindWalk (NASDAQ:HYFTGet Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. Research analysts expect that MindWalk will post -0.21 EPS for the current year.

Hedge Funds Weigh In On MindWalk

Several hedge funds and other institutional investors have recently modified their holdings of HYFT. Bank of Montreal Can grew its holdings in shares of MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the period. Renaissance Technologies LLC increased its position in MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after purchasing an additional 18,600 shares in the last quarter. Jane Street Group LLC raised its holdings in MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after buying an additional 96,018 shares during the period. Bridgeway Capital Management LLC purchased a new position in MindWalk in the fourth quarter valued at approximately $91,000. Finally, XTX Topco Ltd lifted its position in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after buying an additional 44,331 shares in the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

About MindWalk

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

Read More

Analyst Recommendations for MindWalk (NASDAQ:HYFT)

Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.